Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS)
CNY 15.39
(-4.82%)
CNY 15.39
(-4.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -85.28 Million CNY | 70.3% |
| 2022 | -287.18 Million CNY | 19.69% |
| 2021 | -357.57 Million CNY | -3.32% |
| 2020 | -346.08 Million CNY | -1619.06% |
| 2019 | 22.78 Million CNY | 113.9% |
| 2018 | -163.91 Million CNY | 30.11% |
| 2017 | -234.53 Million CNY | -180.24% |
| 2016 | -83.69 Million CNY | -31.67% |
| 2015 | -63.56 Million CNY | -234.68% |
| 2014 | 47.19 Million CNY | 760.84% |
| 2013 | -7.14 Million CNY | -112.59% |
| 2012 | 56.71 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 98.33 Million CNY | 215.31% |
| 2024 Q3 | 74.26 Million CNY | 5.0% |
| 2024 Q2 | 72.43 Million CNY | -26.34% |
| 2023 Q2 | -182.82 Million CNY | 20.69% |
| 2023 FY | -85.28 Million CNY | 70.3% |
| 2023 Q4 | -85.28 Million CNY | 42.08% |
| 2023 Q1 | -230.53 Million CNY | 19.73% |
| 2023 Q3 | -147.24 Million CNY | 19.46% |
| 2022 Q1 | -161.4 Million CNY | 54.86% |
| 2022 FY | -287.18 Million CNY | 19.69% |
| 2022 Q4 | -287.18 Million CNY | -7.08% |
| 2022 Q3 | -268.18 Million CNY | -62.65% |
| 2022 Q2 | -164.88 Million CNY | -2.16% |
| 2021 Q2 | -172.18 Million CNY | 23.63% |
| 2021 Q1 | -225.46 Million CNY | 34.85% |
| 2021 Q4 | -357.57 Million CNY | -71.14% |
| 2021 Q3 | -208.93 Million CNY | -21.34% |
| 2021 FY | -357.57 Million CNY | -3.32% |
| 2020 Q3 | -399.06 Million CNY | -54.17% |
| 2020 Q1 | -205.35 Million CNY | -1001.36% |
| 2020 FY | -346.08 Million CNY | -1619.06% |
| 2020 Q2 | -258.85 Million CNY | -26.05% |
| 2020 Q4 | -346.08 Million CNY | 13.28% |
| 2019 FY | 22.78 Million CNY | 113.9% |
| 2019 Q4 | 22.78 Million CNY | 119.77% |
| 2019 Q3 | -115.25 Million CNY | -16.98% |
| 2019 Q1 | -122.17 Million CNY | 25.47% |
| 2019 Q2 | -98.52 Million CNY | 19.36% |
| 2018 Q1 | -200.39 Million CNY | 14.56% |
| 2018 Q2 | -211.74 Million CNY | -5.66% |
| 2018 Q3 | -208.17 Million CNY | 1.68% |
| 2018 Q4 | -163.91 Million CNY | 21.26% |
| 2018 FY | -163.91 Million CNY | 30.11% |
| 2017 Q3 | -317.09 Million CNY | -1324.36% |
| 2017 Q1 | 176.19 Million CNY | 310.53% |
| 2017 Q2 | -22.26 Million CNY | -112.64% |
| 2017 Q4 | -234.53 Million CNY | 26.04% |
| 2017 FY | -234.53 Million CNY | -180.24% |
| 2016 FY | -83.69 Million CNY | -31.67% |
| 2016 Q4 | -83.69 Million CNY | 0.0% |
| 2015 Q4 | -63.56 Million CNY | 0.0% |
| 2015 Q1 | -3.75 Million CNY | 0.0% |
| 2015 FY | -63.56 Million CNY | -234.68% |
| 2015 Q2 | 12.24 Million CNY | 425.74% |
| 2014 FY | 47.19 Million CNY | 760.84% |
| 2013 FY | -7.14 Million CNY | -112.59% |
| 2012 FY | 56.71 Million CNY | 0.0% |